Thư viện

Nhập Môn Lập Trình Không Code tập trung vào tư duy lập trình – cốt lõi làm nên thành công của bất kỳ nhà phát triển phần mềm nào – nhưng theo một hướng đi hoàn toàn mới: No-code. Đây là xu hướng toàn cầu, cho phép người dùng xây dựng ứng dụng, website, tự động hóa quy trình, thậm chí khởi nghiệp với sản phẩm công nghệ mà không cần viết code bằng ngôn ngữ lập trình. Qua cuốn sách, tác giả không chỉ giới thiệu khái niệm mà còn chia sẻ cách ứng dụng No-code vào thực tế, với tinh thần “người không chuyên cũng làm được”.

A critical challenge for CD47 therapy has always been its presence on healthy red blood cells (RBCs), leading to anemia. In 2026, the "second-generation" of antibodies, such as AK117 and IMC-002, have fundamentally addressed this through structural optimization.

Unlike earlier iterations, 2026 therapeutics often feature optimized binding affinities or selective epitope targeting. Some molecules are engineered to bind more strongly to the clustered CD47 found on tumor cells while showing minimal binding to the sparse CD47 on RBCs. Additionally, "silent" Fc regions are utilized to prevent the antibody from triggering ADCC (Antibody-Dependent Cellular Cytotoxicity) against the healthy cells it might bind to. Clinicians in 2026 also utilize a "priming and maintenance" dosing strategy, which uses a low initial dose to clear older, vulnerable RBCs and stimulate the production of young, resistant reticulocytes before the full therapeutic dose is administered.

Hormonal health in 2026 has expanded to address Polycystic Ovary Syndrome (PCOS) and its long-term metabolic consequences.

• Metabolic Synchronization: Treatment protocols now integrate hormone therapy with metabolic modulators (like GLP-1 agonists or Metformin) to address insulin resistance and androgen dominance.

• Phenotypic Variations: Clinicians now use "Phenotypic Diagnostics" to distinguish between different presentations of PCOS, ensuring that the hormonal intervention—whether for fertility or metabolic health—is precisely targeted.

• Lifestyle Integration: 2026 care models emphasize a "collective approach," where hormonal restoration is supported by specialized nutrition, stress-reduction adaptogens, and resistance training to preserve muscle mass (sarcopenia prevention).

Research institutes in Italy, such as those in Pisa and Florence, are exploring the potential of Quantum Cascade Lasers (QCLs) and high-energy diode systems for the next generation of cancer therapy.

These compact, high-power systems are being developed to create "very brilliant" X-rays and proton beams that can penetrate deeper into the body with less peripheral damage than traditional radiation. The goal is to create mobile therapy units that can be moved between hospital departments, making advanced "Extreme Photonics" treatments accessible to a wider population. This research represents the frontier of Italian medical physics, moving toward a future where light is the primary tool for both diagnosing and curing internal malignancies.